Raltitrexed: Optimism and reality

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 11, 2009, Pages 1447-1454

  Wilson, Kenneth S ^a   Malfair Taylor, Suzanne C ^b  

^a Vancouver Island Cancer Centre   (Canada)

^b Drug Use Optimization BC Ministry of Health   (Australia)

Author keywords

Chemotherapy; Colorectal cancer; Pharmacokinetics; Raltitrexed

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PANITUMUMAB; RALTITREXED; SPARFOSIC ACID; THYMIDYLATE SYNTHASE; TRIMETREXATE;

ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME INHIBITION; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PNEUMONIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TISSUE DISTRIBUTION;

EID: 70449119430     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903307455     Document Type: Review

References (39)

1. Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature 1957;179:663-666
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-944
3. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5FU-based chemotherapy: mutations in the DPD gene and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8:132-138
4. Jackman AL, Boyle ET, Harrap KR. TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 1996;14(3):305-316
5. Editorial. Drug company decision to end cancer trial. Lancet 1999;354:1045
6. Jones ML, Hummel S, Bansback N, et al. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25):1-145. Available from: http://www.hta.ac.uk/ project/1198.asp
7. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation (review of NICE Guidance No. 33). Health Technol Assessment 2008;12(15). Available from: http://www.nice.org.uk/ nicemedia/pdf/word/TA93Guidance.doc. [Accessed July 2009]
8. Saunders MP, Valle JW. Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? Brit J Cancer 2002;86:1667-1669
9. BCCA protocol summary for palliative chemotherapy for metastatic colorectal cancer using raltitrexed in patients with previous 5FU toxicity. Available from: http://www.bccancer.bc.ca/NR/rdonlyres/ C0A8933B-3AAD-4EBA-A95C- 4552A0A060C9/33904/GIRALT0 Protocol01May09.pdf. [Accessed 13 July 2009]
10. Germond C, Maroun J, Zwaal C, Wong S, Gastrointestinal Disease Site Group of Cancer Care Ontario's Program in evidence-based Care. Use of raltitrexed (tomudex) in the management of metastatic colorectal cancer. Practice guideline report #2-17. Filename: pebc2-17f.pdf. Available from: http://www.cancercare.on. ca/search/default. aspx?q?raltitrexed&sortby?Relevance&typ e?-1,1377-78|0,6-76,6-40484&pg?0 [Accessed 1 July 2009]
11. Cassidy J. Thymidylate synthase inhibitors in colorectal cancer. Semin Oncol 2000;27(Suppl 5):83-87
12. Judson IR. Tomudex (raltitrexed) development: preclinical, phase I and II studies. AntiCancer Drugs 1997;8(Suppl 2):S5-9
13. Gunasekara NS, Faulds D. Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998;55(3):423-435
14. Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000;39(5):429-433
15. British Columbia Cancer Agency Monograph: raltitrexed. Health professional information. Available from: http://www.bccancer.bc.ca/NR/ rdonlyres/7E00CDBE-FCA9-43D2-994E-B3ED7DB5A92F/19519/ Raltitrexedmonograph- 3Nov06.pdf [Accessed 1 July 2009]
16. Electronic medicines compendium. Raltitrexed. Available from: http://emc.medicines.org.uk/ medicine/2307/SPC/Tomudex/ [Accessed 1 July 2009]
17. Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997;8(4):407]. Ann Oncol 1996;7(9):961-965
18. Mel JR, Feliu J, Camps C, et al. Tomudex (raltitrexed) in elderly patients with advanced colorectal cancer (ACC): an effective palliative treatment. Proc Am Soc Clin Oncol 2000;19:257a
19. Facchini T, Genet D, Berdah JF, et al. Raltitrexed ('Tomudex') has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: final analysis of a multicentre study. Proc Am Soc Clin Oncol 2000;19:298a
20. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-1106
21. Farrugia DC, Aherne GW, Brunton L, et al. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. Clin Cancer Res 2000;6:3646-3656
22. Pazdur R, Vincent M. Raltitrexed (tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial [abstract 801]. Proc Am Soc Clin Oncol 1997;16:228a
23. Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high- dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16(9):2943-2952
24. Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-1563 Available from: http://linkinghub.elsevier.com/retrieve/pii/ S0140673602085148
25. Thomas RJ, Williams M, Garcia-Vargas J. Lessons learned from raltitrexed - quality assurance, patient education and intensive supportive drugs to optimise tolerability. Clin Oncol 2003;15:227-232
26. Zalcberg J. Overview of the tolerability of tomudex (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997;8(Suppl 2):S17-22
27. Ford HER, Cunningham D. Safety of raltitrexed. Lancet 1999;354:1824-1825
28. Young A, Topham C, Moore J, et al. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. Eur J Cancer 2001;8(3):154-161
29. Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex® ) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008;44(15):2204-2211
30. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-8670
31. Wilson KS, Fitzgerald CA, Barnett JB, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest 2007;25(8):711-714
32. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-3461
33. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5FU/folinic acid with FOLFIRI in patients with complete resection of liver metastases from colorectal cancer. Ann Oncol 2009. Available from: http://annonc.oxfordjournals.org/cgi/ content/abstract/mdp236 [Accessed 30 June 2009]
34. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin in metastatic colorectal cancer. N Engl J Med 2000;343:905-914 Available from: http://content.nejm.org/ cgi/content/abstract/343/13/905
35. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009;27(Suppl 18);abstract LBA4
36. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-2019
37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342 Available from: http://content.nejm.org/cgi/content/ abstract/350/23/2335
38. Van Cutsem E, Cunningham D, Maroun J, et al. Raltitrexed: current status and future directions. Ann Oncol 2002;13:513-522
39. Zalcberg J, Cunningham D, Green M, et al. Proc Am Soc Clin Oncol 1995, abstract 494. Available from: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail- view&confID=28&abstractID=7490